Toll Like Receptor-3 Ligand Poly-ICLC Promotes the Efficacy of Peripheral Vaccinations with Tumor Antigen-derived Peptide Epitopes in Murine CNS Tumor Models

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2007 Feb 14

PMID 17295916

Citations 104

Authors

Xinmei Zhu

Fumihiko Nishimura

Kotaro Sasaki

Mitsugu Fujita

Jill E Dusak

Junichi Eguchi

Wendy Fellows-Mayle

Walter J Storkus

Paul R Walker

Andres M Salazar

Hideho Okada

Affiliations

Soon will be listed here.

Abstract

Background: Toll-like receptor (TLR)3 ligands serve as natural inducers of pro-inflammatory cytokines capable of promoting Type-1 adaptive immunity, and TLR3 is abundantly expressed by cells within the central nervous system (CNS). To improve the efficacy of vaccine strategies directed against CNS tumors, we evaluated whether administration of a TLR3 ligand, polyinosinic-polycytidylic (poly-IC) stabilized with poly-lysine and carboxymethylcellulose (poly-ICLC) would enhance the anti-CNS tumor effectiveness of tumor peptide-based vaccinations.

Methods: C57BL/6 mice bearing syngeneic CNS GL261 glioma or M05 melanoma received subcutaneous (s.c.) vaccinations with synthetic peptides encoding CTL epitopes--mEphA2 (671-679), hgp100 (25-33) and mTRP-2 (180-188) for GL261, or ovalbumin (OVA: 257-264) for M05. The mice also received intramuscular (i.m.) injections with poly-ICLC.

Results: The combination of subcutaneous (s.c.) peptide-based vaccination and i.m. poly-ICLC administration promoted systemic induction of antigen (Ag)-specific Type-1 CTLs expressing very late activation antigen (VLA)-4, which confers efficient CNS-tumor homing of vaccine-induced CTLs based on experiments with monoclonal antibody (mAb)-mediated blockade of VLA-4. In addition, the combination treatment allowed expression of IFN-gamma by CNS tumor-infiltrating CTLs, and improved the survival of tumor bearing mice in the absence of detectable autoimmunity.

Conclusion: These data suggest that poly-ICLC, which has been previously evaluated in clinical trials, can be effectively combined with tumor Ag-specific vaccine strategies, thereby providing a greater index of therapeutic efficacy.

Citing Articles

Challenges and New Directions in Therapeutic Cancer Vaccine Development.

Pan D, Liu J, Huang X, Wang S, Kuerban K, Yan Y Vaccines (Basel). 2025; 12(12.

PMID: 39772003 PMC: 11679661. DOI: 10.3390/vaccines12121341.

Polyinosinic/Polycytidylic Lipid Nanoparticles Enhance Immune Cell Infiltration and Improve Survival in the Glioblastoma Mouse Model.

Brusseler M, Zam A, Moreno-Zafra V, Rouatbi N, Hassuneh O, Marrocu A Mol Pharm. 2024; 21(12):6339-6352.

PMID: 39556101 PMC: 11615939. DOI: 10.1021/acs.molpharmaceut.4c00875.

Immunotherapy for glioblastoma: current state, challenges, and future perspectives.

Liu Y, Zhou F, Ali H, Lathia J, Chen P Cell Mol Immunol. 2024; 21(12):1354-1375.

PMID: 39406966 PMC: 11607068. DOI: 10.1038/s41423-024-01226-x.

Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.

Fei X, Wu J, Tian H, Jiang D, Chen H, Yan K Cancer Biomark. 2024; 41(1):1-24.

PMID: 39240627 PMC: 11492047. DOI: 10.3233/CBM-230486.

Immunotherapy for pediatric low-grade gliomas.

Pollack I, Felker J, Frederico S, Raphael I, Kohanbash G Childs Nerv Syst. 2024; 40(10):3263-3275.

PMID: 38884777 DOI: 10.1007/s00381-024-06491-9.

References

Schmidt K, Leung B, Kwong M, Zarember K, Satyal S, Navas T . APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol. 2003; 172(1):138-43. DOI: 10.4049/jimmunol.172.1.138. View

Walker P, Calzascia T, Schnuriger V, Scamuffa N, Saas P, Tribolet N . The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol. 2000; 165(6):3128-35. DOI: 10.4049/jimmunol.165.6.3128. View

Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E . Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol. 2005; 159(1-2):12-9. DOI: 10.1016/j.jneuroim.2004.09.009. View

Hatano M, Kuwashima N, Tatsumi T, Dusak J, Nishimura F, Reilly K . Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004; 2(1):40. PMC: 535538. DOI: 10.1186/1479-5876-2-40. View

Luft T, Pang K, Thomas E, HERTZOG P, Hart D, Trapani J . Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998; 161(4):1947-53. View

Mailliard R, Son Y, Redlinger R, Coates P, Giermasz A, Morel P . Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003; 171(5):2366-73. DOI: 10.4049/jimmunol.171.5.2366. View

Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak J, Sato H . Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006; 66(11):5883-91. DOI: 10.1158/0008-5472.CAN-06-0363. View

Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P . Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 2002; 99(9):3263-71. DOI: 10.1182/blood.v99.9.3263. View

Hiroishi K, Tuting T, Lotze M . IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol. 2000; 164(2):567-72. DOI: 10.4049/jimmunol.164.2.567. View

10.

Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D . Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003; 4(10):1009-15. DOI: 10.1038/ni978. View

11.

Salem M, El-Naggar S, Kadima A, Gillanders W, Cole D . The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006; 24(24):5119-32. DOI: 10.1016/j.vaccine.2006.04.010. View

12.

Michelsen K, Doherty T, Shah P, Arditi M . TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol. 2004; 173(10):5901-7. DOI: 10.4049/jimmunol.173.10.5901. View

13.

Carter L, Dutton R . Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol. 1996; 8(3):336-42. DOI: 10.1016/s0952-7915(96)80122-1. View

14.

Lang K, Recher M, Junt T, Navarini A, Harris N, Freigang S . Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med. 2005; 11(2):138-45. DOI: 10.1038/nm1176. View

15.

Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak J, Kinch M . EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005; 7(8):717-22. PMC: 1501889. DOI: 10.1593/neo.05277. View

16.

Nishimura F, Dusak J, Eguchi J, Zhu X, Gambotto A, Storkus W . Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006; 66(8):4478-87. DOI: 10.1158/0008-5472.CAN-05-3825. View

17.

Sad S, Marcotte R, Mosmann T . Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity. 1995; 2(3):271-9. DOI: 10.1016/1074-7613(95)90051-9. View

18.

Park C, Lee S, Cho I, Lee H, Kim D, Choi S . TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression. Glia. 2005; 53(3):248-56. DOI: 10.1002/glia.20278. View

19.

Ku C, Yang K, Bustamante J, Puel A, von Bernuth H, Santos O . Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev. 2005; 203:10-20. DOI: 10.1111/j.0105-2896.2005.00235.x. View

20.

Mailliard R, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens C, Kapsenberg M . alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004; 64(17):5934-7. DOI: 10.1158/0008-5472.CAN-04-1261. View